Stereotactic body radiation therapy (SBRT) is an emerging technique used to treat medically inoperable early stage non-small cell lung cancer (NSCLC).Studies have reported that the local control rate of early stage NSCLC treated with SBRT is >80%, and the overall survival for stage Ⅰ disease is >50%.These results are comparable to those of patients subjected to surgery.In the 2011 ASCO annual meeting, researchers from Holland reported a median survival period of 61.5 months for patients with early stage NSCLC and can tolerate surgery resection; a 3-year tumor control rate of >90% was also obtained.Treatment-related morbidities were mild.In the 2012 ASTRO annual meeting, a 5-year cancer-specific survival rate of 63.7%was reported, and this result was approximately equal to that in the operation group (67.1%).